Abstract| Volume 54, ISSUE 5, P739-740, May 2018

Low Dose vs. Standard-Dose Alteplase for Patients With Acute Ischemic Stroke

Wang X, Robinson T, Lee T et al. JAMA Neurol 2017;74(11):1328-1335
      There is developing data for the use of low-dose intravenous alteplase (0.6mg/kg body weight; maximum 60 mg) compared to standard-dose alteplase (0.9mg/kg body weight; maximum 90 mg), however much of this data has been conflicting, especially across different patient populations. In the recently completed alteplase-dose evaluation arm of the Enhanced Control of Hypertension and Thrombolysis Stroke Study (Enchanted), low-dose alteplase was not shown to meet the noninferiority margin defined by the modified Rankin score (mRS) compared to standard-dose alteplase. However, this initial arm did not evaluate the use of low-dose alteplase in specific populations which may benefit from the reduced risk of symptomatic intracerebral hemorrhage (sICH).
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Emergency Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect